Bionomics is a fully integrated, international drug discovery and development company creating new therapies that serve large unmet needs in cancer and central nervous system (CNS) disorders. Based in Adelaide, Australia with operations in San Diego, USA and a wholly owned subsidiary in Strasbourg, France, Bionomics is listed on the Australian Securities Exchange (ASX) under the code BNO, and the US OTCQX market under the code BNOEF.

ASX Announcements

  • BNC105 Clinical Trial in Combination with Nivolumab

    04 January 2019

    Download PDF

  • Bionomics at Neuroscience Innovation Forum and Biotech Showcase

    04 January 2019

    Download PDF

  • Bionomics Receives Over $6.5m R&D Tax Incentive Refund

    11 December 2018

    Download PDF

LATEST CORPORATE PRESENTATION

Latest Analyst Report